Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05647551
Registration number
NCT05647551
Ethics application status
Date submitted
9/12/2022
Date registered
12/12/2022
Date last updated
23/10/2023
Titles & IDs
Public title
A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections
Query!
Scientific title
A Prospective, Open-Label Study to Evaluate Subject's Satisfaction With the Aesthetics of the Periorbital Area After Treatment of the Upper and/or Mid Face With JUVÉDERM® Fillers and BOTOX®/VISTABEL®
Query!
Secondary ID [1]
0
0
2022-000417-13
Query!
Secondary ID [2]
0
0
M22-979
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Facial Corrections
0
0
Query!
Facial Lines
0
0
Query!
Condition category
Condition code
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BOTOX®/VISTABEL®
Treatment: Devices - Juvéderm® VOLBELLA® with Lidocaine
Treatment: Devices - Juvéderm® VOLIFT® with Lidocaine
Treatment: Devices - Juvéderm® VOLUMA® with Lidocaine
Experimental: JUVÉDERM fillers and BOTOX/VISTABEL - At Visit 1, JUVÉDERM filler injections (Juvéderm VOLBELLA with lidocaine, Juvéderm VOLIFT with lidocaine, and/or Juvéderm VOLUMA with lidocaine) will be administered. At Visit 4, JUVÉDERM VOLBELLA with lidocaine, may be administered in the infraorbital hollow (IOH)/tear trough (TT) area. At Visit 6, participants will receive BOTOX/VISTABEL. Touch-ups may be performed as required based on investigator's assessment.
Treatment: Drugs: BOTOX®/VISTABEL®
Facial Injection
Treatment: Devices: Juvéderm® VOLBELLA® with Lidocaine
Facial Injection
Treatment: Devices: Juvéderm® VOLIFT® with Lidocaine
Facial Injection
Treatment: Devices: Juvéderm® VOLUMA® with Lidocaine
Facial Injection
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change from baseline in the overall score of the participant's FACE-Qâ„¢ Satisfaction with Eyes with JUVÉDERM fillers and BOTOX/VISTABEL
Query!
Assessment method [1]
0
0
The FACE-Q Satisfaction with Eyes is a 7-item scale with a 4-point response options ranging from "very dissatisfied" to "very satisfied". The responses will be summed and converted to a Rasch transformed score that ranges from 0 to 100. Higher scores indicate higher satisfaction.
Query!
Timepoint [1]
0
0
Up to 90 Days
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving "Responder" status based on participant's assessment of GAIS of periorbital area
Query!
Assessment method [1]
0
0
The GAIS uses a 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse. A responder is defined as "improved" or "much improved" in the overall aesthetics assessment in the periorbital area.
Query!
Timepoint [1]
0
0
At Day 90
Query!
Secondary outcome [2]
0
0
Percentage of Participant Achieving "Responder" status based on investigator's assessment of GAIS of periorbital area
Query!
Assessment method [2]
0
0
The GAIS uses a 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse. A responder is defined as "improved" or "much improved" in the overall aesthetics assessment in the periorbital area.
Query!
Timepoint [2]
0
0
at Day 90
Query!
Secondary outcome [3]
0
0
Percentage of Participants Achieving "Responder" status based on investigator's assessment of global aesthetic improvement scale (GAIS) of infraorbital area
Query!
Assessment method [3]
0
0
The GAIS uses a 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse. A responder is defined as "improved" or "much improved" in the overall aesthetics assessment in the infraorbital area.
Query!
Timepoint [3]
0
0
At Day 30
Query!
Secondary outcome [4]
0
0
Change from baseline in overall score of the participant's assessment of FACE-Q Psychological Function
Query!
Assessment method [4]
0
0
The FACE-Q Psychological Function is a 10-item scale that measures psychological function with a 4-point response options ranging from "definitely disagree" to "definitely agree". The responses will be summed and converted to a Rasch transformed score that ranges from 0 to 100. Higher scores indicate higher satisfaction.
Query!
Timepoint [4]
0
0
Up to 90 Days
Query!
Eligibility
Key inclusion criteria
- Participant's dissatisfaction with eyes, measured by a baseline score of "very
dissatisfied" or "somewhat dissatisfied" in at least 3 of the 7 items in the FACE-Q
Satisfaction with Eyes.
- Have some degree of IOH/TT per Allergan Infraorbital Hollows Scale (AIHS) (1
[minimal], 2 [moderate], 3 [severe], or 4 [extreme]) on both sides with a chance of
improvement either by direct or indirect treatment, per investigator's assessment.
- Need for treatment in at least 2 areas in the upper and/or mid face (e.g., eyebrows,
IOH/TT, temples, malar or zygomatic, fine lines such as periorbital lines), with at
least two of the JUVÉDERM products (Juvéderm VOLBELLA, Juvéderm VOLIFT, or Juvéderm
VOLUMA), per investigator's assessment.
- Participant meets at least one of the following criteria (investigator's assessment):
- 2 or 3 (moderate or severe) on Allergan Glabellar Lines Severity Scale at maximum
furrow.
- 2 or 3 (moderate or severe) on Lateral Canthal Lines Severity Scale at maximum
smile.
- Participants must have a score of = 5 for Facial Line Outcomes-11 item 1 (Bothered by
Facial Lines).
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Participants with presence of inflammation, infection at any injection site or
systemic infection (study entry may be postponed until one week following recovery),
noticeable acne scarring, cancerous or pre-cancerous lesion, or unhealed wound or have
undergone radiation treatment in the area to be treated.
- Participant with an allergy or sensitivity to investigational products or their
components.
- Participant with history or current symptoms of dysphagia.
- Participant has medical condition that may increase the risk of exposure to botulinum
toxin including diagnosed myasthenia gravis, Eaton-Lambert Syndrome, amyotrophic
lateral sclerosis, or any other disease that might interfere with neuromuscular
function.
- Participant has profound atrophy/excessive weakness of muscles in target areas of
injection.
- Participant has marked facial asymmetry, brow or eyelid ptosis, excessive
dermatochalasis, deep dermal scarring, thick sebaceous skin, or an inability to
substantially lessen the resting Glabellar Lines (GLs) and Lateral Canthal Lines
(LCLs)/facial rhytides by physically spreading them apart.
- Participant has tendency to accumulate fluid in the lower eyelids, or large
infraorbital fat pads, i.e., significant convexity or projection from the infraorbital
fat pads that would mask improvement.
- Participant has mid face volume deficit due to congenital defect, trauma,
abnormalities in adipose tissue related to immune-mediated diseases such as
generalized lipodystrophy (e.g., juvenile dermatomyositis), partial lipodystrophy
(e.g., Barraquer-Simons syndrome), inherited disease, or human immunodeficiency
virus-related disease.
- Participant has undergone live vaccination, surgery, or dental procedures (e.g., tooth
extraction, orthodontia, or implantation) within 30 days prior to enrollment or be
planning to undergo any of these procedures during the study and up to 30 days after
the study.
- Participant has neuromuscular disorders including generalized muscle weakness,
diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise.
- Participant has received temporary or semi-permanent filler injections at upper or mid
face (e.g., HA, calcium hydroxyapatite, L-polylactic acid) within 2 years prior to
entry in the study.
- Participant has received any investigational product or device within 30 days or 5
half-lives of the drug (whichever is longer) prior to study enrollment or planning to
participate in another investigation during the course of this study.
- Participant has undergone at anytime plastic surgery of the face, tissue grafting, or
tissue augmentation with silicone, fat, or other permanent dermal fillers, or be
planning to undergo any of these procedures at any time during the study.
- Participant has received mesotherapy, skin resurfacing (laser, photomodulation,
intense pulsed light, radio frequency, dermabrasion, chemical peel, or non-ablative
procedures) in the face within 6 months prior to study enrollment.
- Participant has a current use of nonsteroidal anti-inflammatory drug (e.g., aspirin,
ibuprofen) with the exception of a daily low dose of aspirin, from 10 days prior to
injection up to 3 days post-injection.
- Participant has had topical retinoid therapy and/or topical hormone cream applied to
the face, for potential participants who have not been on a consistent dose regimen
for at least 6 months prior to enrollment and who are unable to maintain regimen for
the study.
- Participant has received systemic retinoid therapy within one year prior to study
enrollment.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/01/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
5/10/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
73
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Eastern Plastic Surgery /ID# 244785 - Box Hill North
Query!
Recruitment hospital [2]
0
0
Dermatology Institute of Victoria /ID# 244786 - South Yarra
Query!
Recruitment hospital [3]
0
0
Complete Skin Specialists /ID# 244840 - Sunbury
Query!
Recruitment hospital [4]
0
0
SkinBox Clinics /ID# 244787 - Fremantle
Query!
Recruitment postcode(s) [1]
0
0
3129 - Box Hill North
Query!
Recruitment postcode(s) [2]
0
0
3141 - South Yarra
Query!
Recruitment postcode(s) [3]
0
0
3429 - Sunbury
Query!
Recruitment postcode(s) [4]
0
0
6160 - Fremantle
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Bruxelles-Capitale
Query!
Country [2]
0
0
Belgium
Query!
State/province [2]
0
0
Hainaut
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Oost-Vlaanderen
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
West-Vlaanderen
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AbbVie
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Different studies have shown the negative effects of aging around the area of the eyes. Signs
of aging may contribute to erroneously projected emotions (e.g., anger, tiredness, or
sadness) that do not reflect the individual's true feelings affecting interpersonal
relationships. Minimally invasive aesthetic treatments with botulinum toxin and hyaluronic
acid (HA) fillers are used to treat wrinkles and volume deficiencies associated with the
appearance of most of the signs of aging.
This Phase 4 post-marketing study is an open-label study in which all subjects will receive
active study treatment. The purpose of this study is to evaluate the subject's satisfaction
after the treatment of JUVÉDERM® fillers and BOTOX®/VISTABEL® on the upper and/or mid face,
which includes areas around the eyes, under the eyes, eyebrows, the temple, and the cheek.
This study will enroll approximately 80 healthy male and female subjects ages 40 to 65 across
10 sites in Australia, Belgium, and United Kingdom. Each subject will be in the study for
approximately 90 days. The initial treatment of the JUVÉDERM fillers (Juvéderm VOLBELLA with
lidocaine, Juvéderm VOLIFT with lidocaine, and/ or Juvéderm VOLUMA with lidocaine) will be
given on Visit 2, and if needed, a touch-up treatment will be given. On Visit 4, the Juvéderm
VOLBELLA with lidocaine filler, may be given, followed by a touch-up treatment, if needed. On
Visit 6, subjects will receive study drug BOTOX/VISTABEL. All subjects will return for the
study exit visit on Day 90.
There may be higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the study at a hospital or
clinic. The effect of the treatment will be checked by medical assessments, checking for side
effects, and completing questionnaires.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05647551
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
ABBVIE INC.
Query!
Address
0
0
AbbVie
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05647551
Download to PDF